Ciba Ritalin "weak signal" of carcinogenicity in rodent studies subject of Jan. 11 "Dear Doctor" letter.
CIBA-GEIGY RITALIN "WEAK SIGNAL" OF CARCINOGENICITY is the subject of a "Dear Doctor" letter mailed by the company Jan. 11. Requested by FDA and based on a report on a pair of two-year rodent studies of methylphenidate in rats and mice by the National Toxicology Program, the letter states that one study in B6C3F1 mice showed "an increase in hepatocellular adenomas (benign tumors) and, in males only, an increase in hepatoblastomas (rare malignant tumors)."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth